Read More

Palvella Therapeutics And Ligand Pharmaceuticals Expand Strategic Partnership To Accelerate Phase 3 Development Of QTORIN Rapamycin For Microcystic Lymphatic Malformations And Additional High Unmet Need Clinical Indications; Palvella Received $5M Payme…

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with

LGND